The results of this study first showed that, while treatment with the CD38-targeted nanoparticles showed increased accumulation at the tumor site compared to nontargeted nanoparticles, the CD138-targeted nanoparticles showed significantly decreased tumor accumulation, with even lower accumulation at increased CD138pep densities. Here, CD38 is linked to neoplasm.